Celsunax यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

celsunax

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Í fullorðinn sjúklingar, til að hjálpa greina líklega með heilabilun lewy líkama frá alzheimer.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Madopar Hart hylki 100 mg og 25 mg आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

madopar hart hylki 100 mg og 25 mg

roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - hart hylki - 100 mg og 25 mg

Madopar Hart hylki 50 mg og 12,5 mg आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

madopar hart hylki 50 mg og 12,5 mg

roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - hart hylki - 50 mg og 12,5 mg

Madopar Tafla 125 mg आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

madopar tafla 125 mg

roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - tafla - 125 mg

Madopar Depot Hart forðahylki 100 mg/25 mg आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

madopar depot hart forðahylki 100 mg/25 mg

roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - hart forðahylki - 100 mg/25 mg